# Clinical Trials Strategic Planning Subcommittee of CTAC

November 9, 2011



## CTAC Clinical Trials Strategic Planning Subcommittee: Members

<u>CTAC</u>

Joel Tepper (Chair) Jim Abbruzzese Nancy Davidson Nancy Roach George Weiner

#### <u>NCI</u>

Jim Doroshow Jeff Abrams Lori Minasian

# Clinical Trials Strategic Planning Subcommittee: Background and Rationale


- <u>CTWG Evaluation Plan</u>: A plan to assess the performance and impact of several CTWG initiatives on the effectiveness of the NCI clinical trials enterprise was approved by CTAC in July 2011.
- <u>NCI Clinical Trials Network (NCTN)</u>: NCI, Group Chairs and CCOP Research Base PIs need feedback and assistance in assessing priorities across diseases and modalities for the evolving NCTN.
  - This feedback should be provided by thought leaders from within and outside the Groups, and should be part of CTAC
  - This is NOT another level of protocol-specific review
    - Strategy as opposed to tactics
    - Longer-term planning as opposed to short-term objectives

## Clinical Trials Strategic Planning Subcommittee: Purpose and Scope

- Purpose: Advise NCI on the development of a fully integrated clinical trials system.
- Scope: Trials funded through cooperative agreements and contracts.
  - <u>NCI Clinical Trials Network</u> trials reviewed by the Scientific Steering Committees (SSC) and generally conducted by the Cooperative Groups and CCOPs.
  - <u>NCI Early Phase Trials</u> sponsored by CTEP and the Division of Cancer Prevention early phase drug/agent development programs
- Initially focus on the NCI Clinical Trials Network trials.

Clinical Trials Strategic Planning Subcommittee: Objectives

- Monitor and assess the balance, coherence and appropriateness of NCI's clinical trials portfolio.
- Monitor and assess the scientific effectiveness of the NCI's Scientific Steering Committees.
- Recommend new strategies, priorities and directions for clinical trials based on the NCI's current portfolio, evolving clinical needs, and emerging scientific opportunities.
- Monitor and assess other aspects of clinical trials operations across the system including collaboration and timeliness.



\*Adhoc

## NCTN Strategic Planning Working Group: Proposed Categories of Membership

#### Non-NCI

Cooperative Group Chairs Cooperative Group Statisticians Cancer Center Directors CCOP PIs Patient advocates Translational scientists (SPORE/PO1) Cancer Control – Research Base PIs Steering Committee Chairs CTAC members

#### <u>NCI</u>

DCTD

DCP

СССТ

# Next Steps

- NCI to draft function statement and proposed membership for the NCI Clinical Trials Working Group.
  - Subcommittee to provide input to ensure balanced composition.
- NCI to continue implementation of the CTWG Evaluation Plan to generate data for Working Group review.
- Initial Working Group activities:
  - Review responsibilities and tasks
  - Review proposed measures to achieve tasks
  - Develop process for analyzing portfolio and assessing balance based on presentations by NCI staff about the current portfolio.